Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma
A Phase I/II Study to Evaluate the Efficacy and Toxicity of Imatinib Mesylate in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma
Sponsor: M.D. Anderson Cancer Center
Terminated
Study closed following Phase I portion, insufficient activity to continue to Phase II.
Other terminated trials from M.D. Anderson Cancer Center
Other Solid Tumor trials with similar outcome
A PHASE1/PHASE2 clinical study on Solid Tumor and Thyroid Cancer, this trial is terminated or withdrawn. The trial is conducted by M.D. Anderson Cancer Center and has accumulated 5 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
First recorded
Dec 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- M.D. Anderson Cancer Center
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .